Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments - Fair Value Measurements, Additional Information (Details)

v3.19.3
Financial Instruments - Fair Value Measurements, Additional Information (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Payment of contingent consideration $ 500,000 $ 1,000,000.0 $ 3,400,000 $ 2,500,000  
EBITDA metric, measurement component change affected by change in discount rate     2,400,000    
Carrying Value          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term debt, fair value 1,520,000,000   1,520,000,000   $ 5,350,000,000
Estimated Fair Value          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term debt, fair value 1,580,000,000   $ 1,580,000,000   $ 5,350,000,000
Contingent Consideration, Adjusted EBITDA Performance Metric          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Percentage change in rate affecting component measurement (as a percent)     10.00%    
Mac Dermid          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Long-term contingent consideration (up to) 100,000,000   $ 100,000,000    
Price performance metrics period     7 years    
Payment of contingent consideration     $ 40,000,000.0    
Long-term contingent consideration $ 60,000,000.0   60,000,000.0    
Payment of contingent consideration, operating     30,900,000    
Payment of contingent consideration, financing     9,100,000    
Mac Dermid | Contingent Consideration, Adjusted EBITDA Performance Metric          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
Expected future value of payments, target 1     0.0    
Expected future value of payments, target 2     30,000,000.0    
Expected future value of payments, target 3     $ 60,000,000.0    
Mac Dermid | Contingent Consideration, Adjusted EBITDA Performance Metric | Discount Rate          
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]          
EBITDA related earnout include a discount rate (as a percent) 0.105   0.105